Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Sweden
/
Healthcare
Create a narrative
Healthcare Swedish Community
Our community narratives are driven by numbers and valuation.
Create a narrative
All companies
Popular
Undervalued
Overvalued
Healthcare Swedish Investing Ideas
Nanexa
DA
daemningen4500
Community Contributor
19,9% Novo Nordisk ownership on a small swedish biotech - could this be a significant technology?
Nanexa AB is a Swedish pharmaceutical company that specializes in drug delivery systems. Here's a brief overview of its corporate history, ownership, focus, and potential: Corporate History Nanexa was founded in 2007 and is headquartered in Uppsala, Sweden.
View narrative
SEK 1.30
FV
71.2% overvalued
intrinsic discount
28.21%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
about 1 month ago
author updated this narrative
EQL Pharma
MA
Mandelman
Community Contributor
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
2025 Q1 update Strong revenue growth yoy 45% exceding expectations. Strong EPS of 178%, however easy comps should be noted.
View narrative
SEK 86.37
FV
12.4% overvalued
intrinsic discount
30.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
17
users have followed this narrative
3 months ago
author updated this narrative
Dedicare
BO
Bonywall
Community Contributor
Staff Shortages and Demographic Shifts Could Drive Revenue Higher Despite Competition and Regulatory Challenges
Key Takeaways Dedicare holds a robust market position within a steadily expanding market. Continued revenue growth is supported by the persistent need for skilled health professionals.
View narrative
SEK 82.20
FV
46.0% undervalued
intrinsic discount
9.72%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
12 months ago
author updated this narrative
RaySearch Laboratories
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
RayStation And RayCare Upgrades Will Streamline Adaptive Treatment Planning
Key Takeaways Integration of AI and new treatment modules is anticipated to boost efficiency, driving demand and potential revenue growth for RaySearch. Expansion into new applications and increasing integration capabilities may significantly enhance market share and revenue prospects.
View narrative
SEK 335.00
FV
6.1% overvalued
intrinsic discount
13.87%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
3 days ago
author updated this narrative
Senzime
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
US And European Guidelines Will Expand Neuromuscular Monitoring Adoption Worldwide
Key Takeaways Adoption driven by regulatory changes and expansion into new patient segments supports scalable, predictable growth and strengthens market position globally. Product innovation and recurring revenue streams improve margins, offsetting economic headwinds and enhancing long-term earnings stability.
View narrative
SEK 12.80
FV
44.1% undervalued
intrinsic discount
81.30%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
3 days ago
author updated this narrative
OssDsign
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Pure Play Orthobiologics Will Expand US Healthcare Access
Key Takeaways Strategic shift to orthobiologics boosts growth and operational efficiency, enhancing future revenue and sustaining high net margins. U.S. market expansion and distinctive product benefits position OssDsign for significant market share and increased adoption.
View narrative
SEK 15.67
FV
2.5% undervalued
intrinsic discount
28.10%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
3 days ago
author updated this narrative
Sedana Medical
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
US Entry And European Sales Will Expand Market Opportunity
Key Takeaways U.S. market entry and expanding pediatric indications are set to significantly accelerate revenue and long-term growth opportunities. Clinical advantages and operational improvements strengthen market position, support pricing power, and drive sustainable margin expansion.
View narrative
SEK 21.00
FV
21.5% undervalued
intrinsic discount
23.28%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
3 days ago
author updated this narrative
Ambea
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Employee Satisfaction Efforts Will Reduce Turnover Costs And Improve Brand Trust
Key Takeaways Expansion of care services and strategic acquisitions drive revenue growth, enhance economies of scale, and positively impact net margins. Operational efficiencies in existing operations and strategic investments like share buybacks boost profitability, supporting margin stability and increasing investor interest.
View narrative
SEK 131.67
FV
8.9% undervalued
intrinsic discount
7.57%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
3 days ago
author updated this narrative
Elekta
AN
AnalystConsensusTarget
Consensus Narrative from 13 Analysts
AI-Powered Iris Technology Will Strengthen Future Prospects
Key Takeaways Strong order growth and high book-to-bill ratio provide a solid foundation for future revenue and sales growth. AI advancements with Iris technology enhance product differentiation, improving pricing power and elevating margins.
View narrative
SEK 58.58
FV
15.0% undervalued
intrinsic discount
4.09%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
12
users have followed this narrative
3 days ago
author updated this narrative
Value any company in seconds
Popular companies